$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn

$bmrn Overview Financials Valuation SEC Filings Company Website

2012 Q2 Form 10-K Financial Statement

#000119312513077031 Filed on February 26, 2013

Income Statement

Concept	2012 Q2	2012	2011 Q4
Revenue	$124.0M	$500.7M	$107.8M
YoY Change	12.1%	13.45%	6.1%
Cost Of Revenue	$23.57M	$91.83M	$21.50M
YoY Change	22.38%	9.29%	4.88%
Gross Profit	$100.4M	$408.9M	$86.30M
YoY Change	9.93%	14.43%	6.41%
Gross Profit Margin	80.99%	81.66%	80.06%
Selling, General & Admin	$51.54M	$198.2M	$48.50M
YoY Change	25.66%	12.97%	15.2%
% of Gross Profit	51.31%	48.47%	56.2%
Research & Development	$77.81M	$302.2M	$57.90M
YoY Change	47.07%	40.98%	37.2%
% of Gross Profit	77.47%	73.91%	67.09%
Depreciation & Amortization	$8.400M	$34.90M	$9.600M
YoY Change	13.51%	9.4%	21.52%
% of Gross Profit	8.36%	8.54%	11.12%
Operating Expenses	$129.4M	$500.4M	$106.4M
YoY Change	37.72%	28.37%	26.22%
Operating Profit	-$30.95M	-$110.2M	-$20.10M
YoY Change	-4130.47%	225.21%	528.13%
Interest Expense	$1.925M	$7.639M	-$3.300M
YoY Change	-12.54%	-9.16%	43.48%
% of Operating Profit
Other Income/Expense, Net	-$200.0K	-$1.800M	$200.0K
YoY Change	-300.0%	-1900.0%
Pretax Income	-$32.42M	$45.42M	-$23.10M
YoY Change	2663.6%	-28.63%	20.31%
Income Tax	-$411.0K	-$3.931M	$3.600M
% Of Pretax Income		-8.65%
Net Earnings	-$32.01M	-$114.3M	-$26.70M
YoY Change	530.41%	112.4%	118.85%
Net Earnings / Revenue	-25.81%	-22.84%	-24.77%
Basic Earnings Per Share	-$0.27	-$0.95
Diluted Earnings Per Share	-$0.27	-$0.95	-$231.6K
COMMON SHARES
Basic Shares Outstanding	117.9M shares	120.3M shares
Diluted Shares Outstanding	117.9M shares	120.3M shares

Balance Sheet

Concept	2012 Q2	2012	2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$402.6M	$447.8M	$195.1M
YoY Change	55.5%	129.52%	-28.82%
Cash & Equivalents	$177.8M	$180.5M	$46.27M
Short-Term Investments	$224.8M	$267.3M	$148.8M
Other Short-Term Assets	$58.07M	$57.90M	$18.64M
YoY Change	83.78%	45.48%	-44.98%
Inventory	$120.1M	$128.7M	$130.1M
Prepaid Expenses	$14.87M		$7.551M
Receivables	$100.8M	$109.1M	$104.8M
Other Receivables	$9.700M	$0.00	$0.00
Total Short-Term Assets	$681.5M	$743.4M	$469.8M
YoY Change	32.57%	58.24%	-6.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$267.4M	$284.5M	$269.0M
YoY Change	23.5%	5.76%	21.23%
Goodwill	$51.54M		$51.54M
YoY Change			-3.41%
Intangibles	$168.3M		$180.3M
YoY Change			73.93%
Long-Term Investments	$123.2M	$117.1M	$94.90M
YoY Change	-20.16%	23.39%	-26.6%
Other Assets	$20.06M	$208.8M	$15.50M
YoY Change	-91.67%	-13.07%	9.0%
Total Long-Term Assets	$851.0M	$824.9M	$835.9M
YoY Change	11.05%	-1.32%	10.23%
TOTAL ASSETS
Total Short-Term Assets	$681.5M	$743.4M	$469.8M
Total Long-Term Assets	$851.0M	$824.9M	$835.9M
Total Assets	$1.533B	$1.568B	$1.306B
YoY Change	19.69%	20.11%	3.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.50M	$24.00M	$12.24M
YoY Change	71.25%		144.78%
Accrued Expenses	$32.45M	$117.1M	$23.85M
YoY Change	-44.53%	54.89%	-64.88%
Deferred Revenue
YoY Change
Short-Term Debt	$23.40M	$23.40M	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$120.0M	$170.4M	$94.13M
YoY Change	46.34%	81.08%	12.26%
LONG-TERM LIABILITIES
Long-Term Debt	$324.9M	$324.9M	$348.3M
YoY Change	-13.93%	-6.72%	-7.74%
Other Long-Term Liabilities	$87.24M	$57.30M	$19.99M
YoY Change	67.77%	7.91%	-76.2%
Total Long-Term Liabilities	$87.24M	$382.2M	$19.99M
YoY Change	-79.69%	-4.78%	-76.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$120.0M	$170.4M	$94.13M
Total Long-Term Liabilities	$87.24M	$382.2M	$19.99M
Total Liabilities	$532.1M	$552.6M	$532.7M
YoY Change	-2.92%	3.74%	-2.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$481.1M		-$425.1M
YoY Change			14.5%
Common Stock	$1.483B		$1.197B
YoY Change			9.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.000B	$1.016B	$773.0M
YoY Change
Total Liabilities & Shareholders Equity	$1.533B	$1.568B	$1.306B
YoY Change	19.69%	20.11%	3.41%

Cashflow Statement

Concept	2012 Q2	2012	2011 Q4
OPERATING ACTIVITIES
Net Income	-$32.01M	-$114.3M	-$26.70M
YoY Change	530.41%	112.4%	118.85%
Depreciation, Depletion And Amortization	$8.400M	$34.90M	$9.600M
YoY Change	13.51%	9.4%	21.52%
Cash From Operating Activities	-$1.400M	$17.61M	-$100.0K
YoY Change	-110.29%	-4.38%	-99.37%
INVESTING ACTIVITIES
Capital Expenditures	-$9.500M	$44.57M	-$89.70M
YoY Change	375.0%	-39.13%	730.56%
Acquisitions		$0.00
YoY Change
Other Investing Activities	-$142.9M	-$151.1M	$54.80M
YoY Change	-5596.15%	-333.64%	-1989.66%
Cash From Investing Activities	-$152.3M	-$195.6M	-$35.00M
YoY Change	-21857.14%	118.45%	157.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$235.5M	$235.5M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	249.0M	312.3M	10.10M
YoY Change	3051.9%	964.46%	-200.0%
NET CHANGE
Cash From Operating Activities	-1.400M	17.61M	-100.0K
Cash From Investing Activities	-152.3M	-195.6M	-35.00M
Cash From Financing Activities	249.0M	312.3M	10.10M
Net Change In Cash	95.30M	134.3M	-25.00M
YoY Change	329.28%	-421.13%	-36.71%
FREE CASH FLOW
Cash From Operating Activities	-$1.400M	$17.61M	-$100.0K
Capital Expenditures	-$9.500M	$44.57M	-$89.70M
Free Cash Flow	$8.100M	-$26.96M	$89.60M
YoY Change	-48.08%	-50.8%	-1892.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q4	bmrn	Royalty Rate Lower Limit RoyaltyRateLowerLimit	0.07	pure
CY2012Q4	bmrn	Royalty Rate Upper Limit RoyaltyRateUpperLimit	0.10	pure
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	126101610	shares
CY2012Q2	dei	Entity Public Float EntityPublicFloat	2740800000
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	322185000
CY2009Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.04
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	167171000
CY2009Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14046895	shares
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8880548	shares
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	717257000
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	19.15
CY2010Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	31112000
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.08
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88079000
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5125725	shares
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14900241	shares
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	20.92
CY2011Q4	us-gaap	Goodwill Goodwill	51543000
CY2011Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	41803000
CY2011Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	141484000
CY2011Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	5866000
CY2011Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	3101000
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	384716000
CY2011Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	21115000
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance Noncurrent DeferredTaxAssetsValuationAllowanceNoncurrent	5441000
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1197082000
CY2011Q4	us-gaap	Other Assets Current OtherAssetsCurrent	18638000
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	208637000
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15495000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9904117	shares
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	773048000
CY2011Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value Current BusinessAcquisitionContingentConsiderationAtFairValueCurrent	5555000
CY2011Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	72039000
CY2011Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2	196000
CY2011Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	53884000
CY2011Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	9259000
CY2011Q4	us-gaap	Available For Sale Securities Gross Unrealized Gain Loss AvailableForSaleSecuritiesGrossUnrealizedGainLoss	70000
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	12148000
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2011Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17619000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	21.06
CY2011Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2	231000
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	114789732	shares
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	22144000
CY2011Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	75903000
CY2011Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	70744000
CY2011Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	51275000
CY2011Q4	us-gaap	Common Stock Issued Employee Stock Trust CommonStockIssuedEmployeeStockTrust	3935000
CY2011Q4	us-gaap	Liabilities Liabilities	532661000
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12239000
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	36350000
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	33796000
CY2011Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	167000
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	19993000
CY2011Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	148872000
CY2011Q4	us-gaap	Long Term Investments LongTermInvestments	94385000
CY2011Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	3165000
CY2011Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	46272000
CY2011Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	224677000
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-425101000
CY2011Q4	us-gaap	Assets Assets	1305709000
CY2011Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	6530000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	22.33
CY2011Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	37155000
CY2011Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	348329000
CY2011Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	104839000
CY2011Q4	us-gaap	Inventory Net InventoryNet	130118000
CY2011Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	299664000
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1305709000
CY2011Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	49456000
CY2011Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	100000
CY2011Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	6025000
CY2011Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0
CY2011Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	28941000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46272000
CY2011Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	118242000
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	114789732	shares
CY2011Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	180277000
CY2011Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	2036000
CY2011Q4	us-gaap	Available For Sale Securities Debt Maturities Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost	243135000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5506909	shares
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4887000
CY2011Q4	us-gaap	Deferred Compensation Cash Based Arrangements Liability Current DeferredCompensationCashBasedArrangementsLiabilityCurrent	682000
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	23849000
CY2011Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	94125000
CY2011Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	12145000
CY2011Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	7679000
CY2011Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	300000
CY2011Q4	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	1300000
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	94125000
CY2011Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	70396000
CY2011Q4	bmrn	Computer Hardware And Software ComputerHardwareAndSoftware	48566000
CY2011Q4	bmrn	Other Assets Current Fair Value Disclosure OtherAssetsCurrentFairValueDisclosure	4851000
CY2011Q4	bmrn	Other Assets Noncurrent Fair Value Disclosure OtherAssetsNoncurrentFairValueDisclosure	5336000
CY2011Q4	bmrn	Contingent And Deferred Acquisition Payments ContingentAndDeferredAcquisitionPayments	33059000
CY2011Q4	bmrn	Other Liabilities Current Fair Value Disclosure OtherLiabilitiesCurrentFairValueDisclosure	6431000
CY2011Q4	bmrn	Other Liabilities Noncurrent Fair Value Disclosure OtherLiabilitiesNoncurrentFairValueDisclosure	44844000
CY2011Q4	bmrn	Available For Sale Securities Debt Maturities Within Three Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearsAmortizedCost	3100000
CY2011Q4	bmrn	Available For Sale Securities Debt Maturities Within Two Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsAmortizedCost	91163000
CY2011Q4	bmrn	Deferred Tax Assets Credit And Contribution Carry Forwards DeferredTaxAssetsCreditAndContributionCarryForwards	162710000
CY2011Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	513000
CY2011Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2	35000
CY2011Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	231000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16319150	shares
CY2011Q4	us-gaap	Short Term Investments ShortTermInvestments	148820000
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	115000
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2011Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1300000
CY2011Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	8361000
CY2011Q4	us-gaap	Land Land	11608000
CY2011Q4	us-gaap	Assets Current AssetsCurrent	469802000
CY2011Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	42070000
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	251233000
CY2011Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	10957000
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	115745000
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	268971000
CY2011Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	559000
CY2011Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	3000000
CY2011Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	215000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	23.61
CY2011Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	243205000
CY2011Q4	bmrn	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	5979000
CY2011Q4	bmrn	Gross Intangible Assets GrossIntangibleAssets	188638000
CY2011Q4	bmrn	Deferred Tax Liabilities Related To Business Acquisitions DeferredTaxLiabilitiesRelatedToBusinessAcquisitions	35127000
CY2011Q4	bmrn	Deferred Tax Liabilities Related To Joint Venture Basis Difference DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference	1813000
CY2012Q4	us-gaap	Goodwill Goodwill	51543000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	9015000
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	70282000
CY2012Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	144700000
CY2012Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	4991000
CY2012Q4	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	3083000
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	433595000
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	29454000
CY2012Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	225501000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-539448000
CY2012Q4	us-gaap	Assets Assets	1601643000
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance Noncurrent DeferredTaxAssetsValuationAllowanceNoncurrent	6075000
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1561890000
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	25509000
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	221659000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16611000
CY2012Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value BusinessAcquisitionContingentConsiderationAtFairValue	41400000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	8722417	shares
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	1015763000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	6496000
CY2012Q4	us-gaap	Business Acquisition Contingent Consideration At Fair Value Current BusinessAcquisitionContingentConsiderationAtFairValueCurrent	10764000
CY2012Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	79915000
CY2012Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses2	112000
CY2012Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	64300000
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	6179000
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Gain Loss AvailableForSaleSecuritiesGrossUnrealizedGainLoss	194000
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	226600000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	18770000
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2012Q4	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	1685000
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	27530000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	15100000	shares
CY2012Q4	us-gaap	Financing Receivable Recorded Investment Past Due FinancingReceivableRecordedInvestmentPastDue	2538000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	23.30
CY2012Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses2	279000
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	125809162	shares
CY2012Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	43500000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	6990000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	22634000
CY2012Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	71443000
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	116815000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	6749000
CY2012Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	62213000
CY2012Q4	us-gaap	Common Stock Issued Employee Stock Trust CommonStockIssuedEmployeeStockTrust	6603000
CY2012Q4	us-gaap	Liabilities Liabilities	585880000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	23993000
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	43531000
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20431000
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	764000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	26674000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	5780000
CY2012Q4	us-gaap	Long Term Investments LongTermInvestments	115993000
CY2012Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	2072000
CY2012Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	180527000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4444406	shares
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-202000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	875000	shares
CY2012Q4	us-gaap	Available For Sale Securities Debt Maturities Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost	386010000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	22226000
CY2012Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	8403000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	25.69
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	33296000
CY2012Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	324859000
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	109066000
CY2012Q4	us-gaap	Inventory Net InventoryNet	128695000
CY2012Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	578440000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1601643000
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	65918000
CY2012Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	400000
CY2012Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	9625000
CY2012Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	23365000
CY2012Q4	us-gaap	Advance Royalties AdvanceRoyalties	600000
CY2012Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	46533000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	180527000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	118242000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	125809162	shares
CY2012Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	162980000
CY2012Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	2609000
CY2012Q4	us-gaap	Deferred Compensation Cash Based Arrangements Liability Current DeferredCompensationCashBasedArrangementsLiabilityCurrent	6440000
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	43156000
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	147068000
CY2012Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	11943000
CY2012Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	11143000
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	1000000
CY2012Q4	us-gaap	Deferred Rent Receivables Net DeferredRentReceivablesNet	10000000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	170433000
CY2012Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	63689000
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	348000
CY2012Q4	us-gaap	Availableforsale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses2 AvailableforsaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses2	167000
CY2012Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1791000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13869601	shares
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	270211000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	126000
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1306000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	18951000
CY2012Q4	us-gaap	Land Land	11608000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	743462000
CY2012Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	45309000
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	261030000
CY2012Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	17074000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	57256000
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	149122000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	284473000
CY2012Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	1080000
CY2012Q4	us-gaap	Asset Retirement Obligation AssetRetirementObligation	3900000
CY2012Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	75000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	28.83
CY2012Q4	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	3900000
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	386204000
CY2012Q4	bmrn	Deferred Tax Assets Intangible Assets DeferredTaxAssetsIntangibleAssets	6161000
CY2012Q4	bmrn	Computer Hardware And Software ComputerHardwareAndSoftware	56011000
CY2012Q4	bmrn	Other Assets Current Fair Value Disclosure OtherAssetsCurrentFairValueDisclosure	5842000
CY2012Q4	bmrn	Other Assets Noncurrent Fair Value Disclosure OtherAssetsNoncurrentFairValueDisclosure	5867000
CY2012Q4	bmrn	Contingent And Deferred Acquisition Payments ContingentAndDeferredAcquisitionPayments	30618000
CY2012Q4	bmrn	Other Liabilities Current Fair Value Disclosure OtherLiabilitiesCurrentFairValueDisclosure	19967000
CY2012Q4	bmrn	Other Liabilities Noncurrent Fair Value Disclosure OtherLiabilitiesNoncurrentFairValueDisclosure	42646000
CY2012Q4	bmrn	Tax Benefit Measured And Recognized Upon Settlement TaxBenefitMeasuredAndRecognizedUponSettlement	0.50	pure
CY2012Q4	bmrn	Termination Of Collaborative Agreement TerminationOfCollaborativeAgreement	90	Y
CY2012Q4	bmrn	Collaborative Agreement In Terms CollaborativeAgreementInTerms	10	Y
CY2012Q4	bmrn	Available For Sale Securities Debt Maturities Within Four Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinFourYearsAmortizedCost	60856000
CY2012Q4	bmrn	Available For Sale Securities Debt Maturities Within Three Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinThreeYearsAmortizedCost	55085000
CY2012Q4	bmrn	Available For Sale Securities Debt Maturities Within Two Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsAmortizedCost	270069000
CY2012Q4	bmrn	Deferred Tax Liabilities Deferred Expense Future Amortization Or Possible Impairment Associated With Intangible Assets DeferredTaxLiabilitiesDeferredExpenseFutureAmortizationOrPossibleImpairmentAssociatedWithIntangibleAssets	31400000
CY2012Q4	bmrn	Deferred Tax Assets Credit And Contribution Carry Forwards DeferredTaxAssetsCreditAndContributionCarryForwards	170322000
CY2012Q4	bmrn	Gross Intangible Assets GrossIntangibleAssets	181931000
CY2012Q4	bmrn	Deferred Tax Liabilities Related To Business Acquisitions DeferredTaxLiabilitiesRelatedToBusinessAcquisitions	31420000
CY2012Q4	bmrn	Deferred Tax Liabilities Related To Joint Venture Basis Difference DeferredTaxLiabilitiesRelatedToJointVentureBasisDifference	1801000
CY2011Q4	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	81000000
CY2012Q4	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses	6000000
CY2012Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	235500000
CY2012Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	6500000	shares
CY2012Q2	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	36.28
CY2010	us-gaap	Costs And Expenses CostsAndExpenses	375723000
CY2010	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1900000
CY2010	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeTax	-473000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	18000000
CY2010	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	221659000
CY2010	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27737000
CY2010	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	10.577	pure
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	544000
CY2010	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	369701000
CY2010	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2010	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	390000
CY2010	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	32950000
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	38362000
CY2010	us-gaap	Contracts Revenue ContractsRevenue	682000
CY2010	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	205074000
CY2010	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3268000
CY2010	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	541000
CY2010	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	33103000
CY2010	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	3633000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0.000	pure
CY2010	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	19129000	shares
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	38362000
CY2010	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	21.63
CY2010	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.73
CY2010	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2166000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	23.80
CY2010	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-3239000
CY2010	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-213796000
CY2010	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	2041980	shares
CY2010	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	119562000
CY2010	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	485000
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-50149000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.233	pure
CY2010	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	289000
CY2010	us-gaap	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	2400000
CY2010	us-gaap	Derivative Instruments Loss Recognized In Other Comprehensive Income Effective Portion DerivativeInstrumentsLossRecognizedInOtherComprehensiveIncomeEffectivePortion	200000
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	18746000
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-101342000
CY2010	us-gaap	Investment Income Interest InvestmentIncomeInterest	4112000
CY2010	us-gaap	Income Taxes Paid IncomeTaxesPaid	3581000
CY2010	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3777000
CY2010	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-16377000
CY2010	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax	4211000
CY2010	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-3726000
CY2010	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	14.44
CY2010	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.063	pure
CY2010	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	489000
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	28659000
CY2010	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103093000	shares
CY2010	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	31036000
CY2010	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1355000
CY2010	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	49461000
CY2010	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-79092000
CY2010	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	118242000
CY2010	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
CY2010	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125674000	shares
CY2010	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses	15861000
CY2010	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2403000	shares
CY2010	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29463000
CY2010	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	14084000
CY2010	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13036000
CY2010	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2000
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-21490000
CY2010	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-745000
CY2010	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.00
CY2010	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	147309000
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3504000
CY2010	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax	-148000
CY2010	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	1549000
CY2010	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	755000
CY2010	us-gaap	Cost Of Revenue CostOfRevenue	70285000
CY2010	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	902000
CY2010	us-gaap	Royalty Revenue RoyaltyRevenue	5884000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.892	pure
CY2010	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	700000
CY2010	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	541000
CY2010	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	4220000
CY2010	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5100000
CY2010	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	9977000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2010	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2991000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	659606	shares
CY2010	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	206361000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.016	pure
CY2010	us-gaap	Revenues Revenues	376267000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	11.767	pure
CY2010	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1624000
CY2010	us-gaap	Depreciation Depreciation	23300000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.127	pure
CY2010	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	37492000
CY2010	bmrn	Effective Income Tax Rate Reconciliation At Nondeductible Acquisition Expenses EffectiveIncomeTaxRateReconciliationAtNondeductibleAcquisitionExpenses	-0.019	pure
CY2010	bmrn	Effective Income Tax Rate Reconciliation At Nondeductible Debt Conversion Expense EffectiveIncomeTaxRateReconciliationAtNondeductibleDebtConversionExpense	-0.109	pure
CY2010	bmrn	Sales Revenue Goods Net Percentages SalesRevenueGoodsNetPercentages	1.00	pure
CY2010	bmrn	Percentage Of Net Product Revenue Attributed To Largest Customers PercentageOfNetProductRevenueAttributedToLargestCustomers	0.46	pure
CY2010	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	5326000
CY2010	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	13728000
CY2010	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	195000
CY2010	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-4453000
CY2010	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	418000
CY2010	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	0
CY2010	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2010	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-137000
CY2010	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-230577000
CY2010	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1320000
CY2010	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12735000	shares
CY2010	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-404000
CY2010	us-gaap	Net Income Loss NetIncomeLoss	205819000
CY2010	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	541000
CY2010	us-gaap	Interest Paid Net InterestPaidNet	10077000
CY2010	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	151723000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	3554932	shares
CY2010	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-227309000
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	205819000
CY2010	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-250000
CY2010	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1983000
CY2010	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1313000
CY2010	us-gaap	Interest Expense InterestExpense	10818000
CY2010	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	217345000
CY2010	us-gaap	Debt Instrument Convertible Interest Expense DebtInstrumentConvertibleInterestExpense	10000000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.25
CY2010	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1228000
CY2010	bmrn	Stockbased Compensation Capitalized StockbasedCompensationCapitalized	5139000
CY2010	bmrn	Supplemental Accrued Expenses SupplementalAccruedExpenses	4957000
CY2010	bmrn	Change Of Business Acquisition Contingent Consideration At Fair Value ChangeOfBusinessAcquisitionContingentConsiderationAtFairValue	-3989000
CY2010	bmrn	Gain Loss On Conversion Of Securities GainLossOnConversionOfSecurities	0
CY2010	bmrn	Effective Income Tax Rate Reconciliation At Changes In Fair Value Of Contingent Acquisition Consideration Payable EffectiveIncomeTaxRateReconciliationAtChangesInFairValueOfContingentAcquisitionConsiderationPayable	-0.065	pure
CY2010	bmrn	Potentially Issuable Restricted Common Stock PotentiallyIssuableRestrictedCommonStock	286000	shares
CY2010	bmrn	Dilutive Potentially Issuable Common Stock For Espp Purchases DilutivePotentiallyIssuableCommonStockForEsppPurchases	763000	shares
CY2010	bmrn	Stock Based Compensation Capitalized To Inventory StockBasedCompensationCapitalizedToInventory	5100000
CY2010	bmrn	Common Shares Transferred Into Nonqualified Deferred Compensation Plan CommonSharesTransferredIntoNonqualifiedDeferredCompensationPlan	250000
CY2010	bmrn	Asset Retirement Restricted Assets Fair Value AssetRetirementRestrictedAssetsFairValue	0
CY2010	bmrn	Intangible Asset Amortization And Contingent Consideration IntangibleAssetAmortizationAndContingentConsideration	6406000
CY2010	bmrn	Depreciation Expense Capitalized Into Inventory DepreciationExpenseCapitalizedIntoInventory	5088000
CY2010	bmrn	Reversal Of Deferred Tax Assets Valuation Allowance ReversalOfDeferredTaxAssetsValuationAllowance	230600000
CY2010	bmrn	Effective Income Tax Rate Reconciliation At Section One Hundred Sixty Two Limitation EffectiveIncomeTaxRateReconciliationAtSectionOneHundredSixtyTwoLimitation	-0.016	pure
CY2011	us-gaap	Costs And Expenses CostsAndExpenses	475248000
CY2011	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	1962000
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeTax	1648000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	25100000
CY2011	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	215429000
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-33890000
CY2011	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	437647000
CY2011	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-229000
CY2011	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	43909000
CY2011	us-gaap	Contracts Revenue ContractsRevenue	468000
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-49137000
CY2011	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5846000
CY2011	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	415000
CY2011	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	33592000
CY2011	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1903000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	0.010	pure
CY2011	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	43909000
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	27.89
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4660000
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	10109000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	24.70
CY2011	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-2543000
CY2011	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	7398000
CY2011	us-gaap	Derivative Instruments Gain Recognized In Other Comprehensive Income Effective Portion DerivativeInstrumentsGainRecognizedInOtherComprehensiveIncomeEffectivePortion	8000000
CY2011	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1923455	shares
CY2011	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	29192000
CY2011	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	5174000
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-107267000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.439	pure
CY2011	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2766000
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	36094000
CY2011	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.234	pure
CY2011	us-gaap	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	3200000
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	18753000
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-89560000
CY2011	us-gaap	Investment Income Interest InvestmentIncomeInterest	2934000
CY2011	us-gaap	Income Taxes Paid IncomeTaxesPaid	4395000
CY2011	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	4411000
CY2011	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2957000
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax	-2989000
CY2011	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	8163000
CY2011	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	15.42
CY2011	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.019	pure
CY2011	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	60000
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	73219000
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-41807000
CY2011	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	28982000
CY2011	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	112122000	shares
CY2011	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses	1894000
CY2011	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29712000
CY2011	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	2234000
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	18456000
CY2011	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	6000
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-43627000
CY2011	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	4699000
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	214374000
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29000000
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax	12000
CY2011	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	0
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	27000
CY2011	us-gaap	Cost Of Revenue CostOfRevenue	84023000
CY2011	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0
CY2011	us-gaap	Royalty Revenue RoyaltyRevenue	3243000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.867	pure
CY2011	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	415000
CY2011	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-7174000
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	63640000
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	112122000	shares
CY2011	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	20420000
CY2011	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1439000
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	6000000
CY2011	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2011	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1800000
CY2011	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2426000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	525100	shares
CY2011	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	281991000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.013	pure
CY2011	us-gaap	Revenues Revenues	441358000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.050	pure
CY2011	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1641000
CY2011	us-gaap	Depreciation Depreciation	31900000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.082	pure
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	43819000
CY2011	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	837000
CY2011	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1896000
CY2011	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	879000
CY2011	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-4036000
CY2011	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	-4500000
CY2011	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	0
CY2011	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	81000000
CY2011	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-531000
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4363000
CY2011	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	210000
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35173000	shares
CY2011	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-78000
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-53836000
CY2011	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	415000
CY2011	us-gaap	Interest Paid Net InterestPaidNet	7215000
CY2011	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	175423000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	3867464	shares
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10209000
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-53836000
CY2011	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-1970000
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-508000
CY2011	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	500000
CY2011	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	286000
CY2011	us-gaap	Interest Expense InterestExpense	8409000
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-53836000
CY2011	us-gaap	Debt Instrument Convertible Interest Expense DebtInstrumentConvertibleInterestExpense	7400000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	13.60
CY2011	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-481000
CY2011	bmrn	Stockbased Compensation Capitalized StockbasedCompensationCapitalized	5298000
CY2011	bmrn	Supplemental Accrued Expenses SupplementalAccruedExpenses	320000
CY2011	bmrn	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	578000
CY2011	bmrn	Change Of Business Acquisition Contingent Consideration At Fair Value ChangeOfBusinessAcquisitionContingentConsiderationAtFairValue	1795000
CY2011	bmrn	Gain Loss On Conversion Of Securities GainLossOnConversionOfSecurities	0
CY2011	bmrn	Number Of Customers Accounted For Largest Balance In Account Receivable NumberOfCustomersAccountedForLargestBalanceInAccountReceivable	2	Customer
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	610938000
CY2011	bmrn	Effective Income Tax Rate Reconciliation At Changes In Fair Value Of Contingent Acquisition Consideration Payable EffectiveIncomeTaxRateReconciliationAtChangesInFairValueOfContingentAcquisitionConsiderationPayable	0.015	pure
CY2011	bmrn	Effective Income Tax Rate Reconciliation At Nondeductible Acquisition Expenses EffectiveIncomeTaxRateReconciliationAtNondeductibleAcquisitionExpenses	-0.002	pure
CY2011	bmrn	Effective Income Tax Rate Reconciliation At Nondeductible Debt Conversion Expense EffectiveIncomeTaxRateReconciliationAtNondeductibleDebtConversionExpense	-0.006	pure
CY2011	bmrn	Sales Revenue Goods Net Percentages SalesRevenueGoodsNetPercentages	1.00	pure
CY2011	bmrn	Percentage Of Net Product Revenue Attributed To Largest Customers PercentageOfNetProductRevenueAttributedToLargestCustomers	0.46	pure
CY2011	bmrn	Potentially Issuable Restricted Common Stock PotentiallyIssuableRestrictedCommonStock	0	shares
CY2011	bmrn	Dilutive Potentially Issuable Common Stock For Espp Purchases DilutivePotentiallyIssuableCommonStockForEsppPurchases	0	shares
CY2011	bmrn	Stock Based Compensation Capitalized To Inventory StockBasedCompensationCapitalizedToInventory	5300000
CY2011	bmrn	Common Shares Transferred Into Nonqualified Deferred Compensation Plan CommonSharesTransferredIntoNonqualifiedDeferredCompensationPlan	1970000
CY2011	bmrn	Asset Retirement Restricted Assets Fair Value AssetRetirementRestrictedAssetsFairValue	2991000
CY2011	bmrn	Intangible Asset Amortization And Contingent Consideration IntangibleAssetAmortizationAndContingentConsideration	1428000
CY2011	bmrn	Depreciation Expense Capitalized Into Inventory DepreciationExpenseCapitalizedIntoInventory	6576000
CY2011	bmrn	Effective Income Tax Rate Reconciliation At Section One Hundred Sixty Two Limitation EffectiveIncomeTaxRateReconciliationAtSectionOneHundredSixtyTwoLimitation	-0.009	pure
CY2012	dei	Trading Symbol TradingSymbol	BMRN
CY2012	dei	Entity Registrant Name EntityRegistrantName	BIOMARIN PHARMACEUTICAL INC
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0001048477
CY2012	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	6034000
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeTax	-2153000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	94600000
CY2012	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	382168000
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-110215000
CY2012	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	496497000
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	235499000
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	-140000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M24D
CY2012	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	47340000
CY2012	us-gaap	Contracts Revenue ContractsRevenue	1955000
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-119436000
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	5990000
CY2012	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	473000
CY2012	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	81402000
CY2012	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1743000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Deductions Other EffectiveIncomeTaxRateReconciliationDeductionsOther	-0.011	pure
CY2012	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	47340000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	37.70
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.95
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	7190000
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	37411000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	26.14
CY2012	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	3506000
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-6055000
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4097279	shares
CY2012	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	105000
CY2012	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><b>(2) BASIS OF PRESENTATION</b></font></p> <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><i>Basis of Presentation</i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">These Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and include the accounts of BioMarin and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated. Management performed an evaluation of the Company’s activities through the date of filing of this Annual Report on Form 10-K, and has concluded that there are no subsequent events except for the transaction disclosed in Note 24.</font></p> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><i>Use of Estimates</i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> </div>
CY2012	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	-5066000
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-163700000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.276	pure
CY2012	us-gaap	Derivative Instruments Loss Recognized In Other Comprehensive Income Effective Portion DerivativeInstrumentsLossRecognizedInOtherComprehensiveIncomeEffectivePortion	200000
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	17609000
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2253000
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	45295000
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.033	pure
CY2012	us-gaap	Amortization Of Acquired Intangible Assets AmortizationOfAcquiredIntangibleAssets	3200000
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-195645000
CY2012	us-gaap	Investment Income Interest InvestmentIncomeInterest	2584000
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	6582000
CY2012	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5495000
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3891000
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment On Derivatives Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentOnDerivativesIncludedInNetIncomeNetOfTax	3683000
CY2012	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-8749000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	18.95
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.013	pure
CY2012	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1787000
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	235499000
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	44571000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	134255000
CY2012	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	105000
CY2012	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	4076000
CY2012	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	6707000
CY2012	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	0
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4227000
CY2012	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-301000
CY2012	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(4) RECENT ACCOUNTING PRONOUNCEMENTS</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2">In August 2012, the FASB issued ASU 2012-03, <i>Technical Amendments and Corrections to SEC Sections: Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 114 (SAB No. 114), Technical Amendments Pursuant to SEC Release No. 33-9250, and Corrections Related to FASB Accounting Standards Update 2010-22</i> (ASU 2012-03). The update amends various SEC paragraphs pursuant to the issuance of SAB No. 114 and is effective upon issuance. The adoption of the amended guidance in ASU 2012-03 did not have a significant impact on the Company’s Consolidated Financial Statements.</font></font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: Times New Roman" size="2">In October 2012, the FASB issued ASU 2012-04, <i>Technical Corrections and Improvements</i> (ASU 2012-04). The amendments in this update cover a wide range of Topics in the Accounting Standards Codification including technical corrections and improvements to the Accounting Standards Codification and conforming amendments related to fair value measurements. The amendments in ASU 2012-04 are effective for fiscal periods beginning after December 15, 2012, which for the Company means January 1, 2013. The adoption of ASU 2012-04 is not expected to have a material impact on the Company’s Consolidated Financial Statements.</font></font></p> </div>
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	120271000	shares
CY2012	us-gaap	Other Payments To Acquire Businesses OtherPaymentsToAcquireBusinesses	4405000
CY2012	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77566000
CY2012	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeNetOfTax	-110000
CY2012	us-gaap	Cost Of Revenue CostOfRevenue	91830000
CY2012	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-118278000
CY2012	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-5089000
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.95
CY2012	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><b>(1) NATURE OF OPERATIONS AND BUSINESS RISKS</b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">BioMarin Pharmaceutical Inc. (the Company or BioMarin), a Delaware corporation, develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. BioMarin selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s product portfolio is comprised of four approved products and multiple investigational product candidates. The Company’s approved products are Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Firdapse (amifampridine phosphate) and Aldurazyme (laronidase).</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">Through December 31, 2012, the Company had accumulated losses of approximately $539.4 million. Management believes that the Company’s cash, cash equivalents and short-term and long-term investments at December 31, 2012 will be sufficient to meet the Company’s obligations for at least the next twelve months based on management’s current business plans. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital. The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents, short-term and long-term investments, and to the extent necessary, through proceeds from equity or debt financings, loans and collaborative agreements with corporate partners.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The Company is subject to a number of risks, including: the financial performance of Naglazyme, Kuvan, Firdapse and Aldurazyme; the potential need for additional financings; its ability to successfully commercialize its product candidates, if approved; the uncertainty of the Company’s research and development efforts resulting in future successful commercial products; obtaining regulatory approval for new products; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the health care industry.</font></p> </div>
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	302218000
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	312291000
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment For Sale Of Securities Included In Net Income Tax OtherComprehensiveIncomeLossReclassificationAdjustmentForSaleOfSecuritiesIncludedInNetIncomeTax	40000
CY2012	us-gaap	Amortization Of Deferred Loan Origination Fees Net AmortizationOfDeferredLoanOriginationFeesNet	0
CY2012	us-gaap	Royalty Revenue RoyaltyRevenue	2271000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.500	pure
CY2012	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	473000
CY2012	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	6529000
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	45422000
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	120271000	shares
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1423000
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1879000
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	10100000
CY2012	us-gaap	Depreciation Depreciation	34900000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.016	pure
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	47972000
CY2012	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	600000
CY2012	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1221000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	648840	shares
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2012	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	237837000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.009	pure
CY2012	us-gaap	Revenues Revenues	500723000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.006	pure
CY2012	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1858000
CY2012	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	678000
CY2012	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-4469000
CY2012	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax	5114000
CY2012	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	5000000
CY2012	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2012	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-1659000
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-9921000
CY2012	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32921000	shares
CY2012	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	25000
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-114347000
CY2012	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	473000
CY2012	us-gaap	Interest Paid Net InterestPaidNet	6665000
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	198173000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	2296570	shares
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3931000
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-114347000
CY2012	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><i>Use of Estimates</i></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> </div>
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-2668000
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	388000
CY2012	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	6800000
CY2012	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0
CY2012	bmrn	Excess Of Amount For Financial Reporting Over Tax Basis Of Investments In Foreign Subsidiaries ExcessOfAmountForFinancialReportingOverTaxBasisOfInvestmentsInForeignSubsidiaries	1400000
CY2012	us-gaap	Interest Expense InterestExpense	7639000
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-114347000
CY2012	us-gaap	Debt Instrument Convertible Interest Expense DebtInstrumentConvertibleInterestExpense	6700000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	16.98
CY2012	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	278000
CY2012	bmrn	Stockbased Compensation Capitalized StockbasedCompensationCapitalized	4347000
CY2012	bmrn	Supplemental Accrued Expenses SupplementalAccruedExpenses	511000
CY2012	bmrn	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-9000
CY2012	bmrn	Change Of Business Acquisition Contingent Consideration At Fair Value ChangeOfBusinessAcquisitionContingentConsiderationAtFairValue	-8788000
CY2012	bmrn	Gain Loss On Conversion Of Securities GainLossOnConversionOfSecurities	-2000000
CY2012	bmrn	Lease Expiration Year LeaseExpirationYear	2022
CY2012	bmrn	Number Of Customers Accounted For Largest Balance In Account Receivable NumberOfCustomersAccountedForLargestBalanceInAccountReceivable	2	Customer
CY2012	bmrn	Effective Income Tax Rate Reconciliation At Changes In Fair Value Of Contingent Acquisition Consideration Payable EffectiveIncomeTaxRateReconciliationAtChangesInFairValueOfContingentAcquisitionConsiderationPayable	-0.026	pure
CY2012	bmrn	Effective Income Tax Rate Reconciliation At Nondeductible Acquisition Expenses EffectiveIncomeTaxRateReconciliationAtNondeductibleAcquisitionExpenses	0.000	pure
CY2012	bmrn	Effective Income Tax Rate Reconciliation At Nondeductible Debt Conversion Expense EffectiveIncomeTaxRateReconciliationAtNondeductibleDebtConversionExpense	0.000	pure
CY2012	bmrn	Sales Revenue Goods Net Percentages SalesRevenueGoodsNetPercentages	1.00	pure
CY2012	bmrn	Percentage Of Product Revenue Exceeding Consolidated Net Product Revenue PercentageOfProductRevenueExceedingConsolidatedNetProductRevenue	0.10	pure
CY2012	bmrn	Percentage Of Share In Gain Loss From Joint Ventures PercentageOfShareInGainLossFromJointVentures	0.50	pure
CY2012	bmrn	Percentage Of Net Product Revenue Attributed To Largest Customers PercentageOfNetProductRevenueAttributedToLargestCustomers	0.43	pure
CY2012	bmrn	Number Of Options Available In Money NumberOfOptionsAvailableInMoney	13800000	shares
CY2012	bmrn	Potentially Issuable Restricted Common Stock PotentiallyIssuableRestrictedCommonStock	0	shares
CY2012	bmrn	Dilutive Potentially Issuable Common Stock For Espp Purchases DilutivePotentiallyIssuableCommonStockForEsppPurchases	0	shares
CY2012	bmrn	Share Based Compensation Arrangement By Share Based Payment Award Vesting Period ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriod	1	Y
CY2012	bmrn	Common Shares Transferred Into Nonqualified Deferred Compensation Plan CommonSharesTransferredIntoNonqualifiedDeferredCompensationPlan	0
CY2012	bmrn	Asset Retirement Restricted Assets Fair Value AssetRetirementRestrictedAssetsFairValue	886000
CY2012	bmrn	Stock Based Compensation Capitalized To Inventory StockBasedCompensationCapitalizedToInventory	4300000
CY2012	bmrn	Contingent Payments Upon Achievement Of Certain Regulatory And Licensing Milestones ContingentPaymentsUponAchievementOfCertainRegulatoryAndLicensingMilestones	285500000
CY2012	bmrn	Intangible Asset Amortization And Contingent Consideration IntangibleAssetAmortizationAndContingentConsideration	18717000
CY2012	bmrn	Depreciation Expense Capitalized Into Inventory DepreciationExpenseCapitalizedIntoInventory	7335000
CY2012	bmrn	Effective Income Tax Rate Reconciliation At Section One Hundred Sixty Two Limitation EffectiveIncomeTaxRateReconciliationAtSectionOneHundredSixtyTwoLimitation	-0.012	pure
CY2012Q1	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	6700000

Files In Submission

Name	View Source	Status
0001193125-13-077031-index-headers.html	Edgar Link	pending
0001193125-13-077031-index.html	Edgar Link	pending
0001193125-13-077031.txt	Edgar Link	pending
0001193125-13-077031-xbrl.zip	Edgar Link	pending
bmrn-20121231.xml	Edgar Link	completed
bmrn-20121231.xsd	Edgar Link	pending
bmrn-20121231_cal.xml	Edgar Link	unprocessable
bmrn-20121231_def.xml	Edgar Link	unprocessable
bmrn-20121231_lab.xml	Edgar Link	unprocessable
bmrn-20121231_pre.xml	Edgar Link	unprocessable
d455570d10k.htm	Edgar Link	pending
d455570dex1060.htm	Edgar Link	pending
d455570dex211.htm	Edgar Link	pending
d455570dex231.htm	Edgar Link	pending
d455570dex232.htm	Edgar Link	pending
d455570dex311.htm	Edgar Link	pending
d455570dex312.htm	Edgar Link	pending
d455570dex321.htm	Edgar Link	pending
d455570dex991.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g455570g41e36.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn

2012 Q2 Form 10-K Financial Statement

#000119312513077031 Filed on February 26, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRN BIOMARIN PHARMACEUTICAL INC Stock $bmrn

2012 Q2 Form 10-K Financial Statement

#000119312513077031 Filed on February 26, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BMRN
BIOMARIN PHARMACEUTICAL INC Stock $bmrn